Please assess the completion status of the following clinical trial:

Trial Title: Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently participating in Study MLN-MD-06~* Receiving a stable dosage of milnacipran (50-200 mg/d) at Screening/Enrollment (Visit 1)~Exclusion Criteria:~* Significant risk of suicide~* History of mania, bipolar disorder, psychotic disorder, schizophrenia, or a current episode of major depressive disorder~* Myocardial infarction and/or stroke within the prior 12 months~* Mean systolic blood pressure \> 180 mm Hg or mean diastolic blood pressure \> 110 mm Hg at Screening (Visit 1)~* Active liver disease~* Severe renal impairment~* Platelet and bleeding disorders~* Female patients who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo tablets administered orally twice daily
- 2 (Type: EXPERIMENTAL): Milnacipran tablets administered orally twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).